CME Presentations
Annual Rare Cancers and Blood Disorders Series
Presentations
AL Amyloidosis: A Rare Blood Disorder with Multi-Organ Complications
Speakers: Vaishali Sanchorawala, MD, Professor of MedicineHans Lee, MD, Assistant Professor, Department of Lymphoma/Myeloma Duration: 60 minutes
Presented on: April 20, 2022
Refining Management of Classical Hodgkin Lymphoma: What’s on the Horizon for Pediatric Management and AYA Survivorship
Speakers: Lisa Roth, MD, Director, Pediatric OncologySharon Castellino, MD, MSc, Professor of Pediatrics Duration: 60 minutes
Presented on: December 20, 2022
Cold Agglutinin Disease (CAD): Impact of a Rare Anemia and the Promise of New Therapies
Speakers: Shirley D'Sa, MD, FRCP, FRCPath, Haematologist and Associate Professor Duration: 30 minutes
Presented on: April 29, 2022
New Treatment Options for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Community
Speakers: Carlos de Castro, MD, Professor of Medicine, Division of Hematologic Malignancies & Cell Therapy Duration: 30 minutes
Presented on: April 29, 2022
Systemic Therapy for Symptomatic Patients with Waldenström’s Macroglobulinemia
Speakers: Jorge Castillo, MD, Clinical DirectorAdam Olszewski, MD, Associate Professor of Medicine Duration: 60 minutes
Presented on: June 1, 2022
Improving Quality of Life with Treatment Approaches in Graft versus Host Disease
Speakers: Zachariah DeFilipp, MD, Director of BMT Clinical ResearchYi-Bin Chen, MD, MS, Director, Hematopoietic Cell Transplant & Cell Therapy Program Duration: 60 minutes
Presented on: June 9, 2022
CD30‐Targeted Treatment Approaches for Patients with PTCL and CTCL
Speakers: Lauren Pinter-Brown, MD, FACP, Health Sciences Professor of Medicine and Dermatology Duration: 30 minutes
Presented on: August 17, 2022
Speakers
Vaishali Sanchorawala, MD
Vaishali Sanchorawala, MD
Professor of Medicine
Vaishali Sanchorawala, MD, is the Professor of Medicine and Director of the Amyloidosis Center of Boston University School of Medicine and Boston Medical Center. She is a pioneer of clinical research in AL amyloidosis, and her work in the treatment of AL amyloidosis has been published in many peer-reviewed journals, resulting in the evolution of the standard of care for patients. Dr. Sanchorawala is currently heading several clinical trials in the treatment of AL amyloidosis. She serves on the executive steering committee of the Amyloidosis Research Consortium, secretary of the board of the International Society of Amyloidosis, and associate editor of Amyloid, Journal of Protein Folding Disorders. She has helped cultivate the next generation of physician-scientists in AL amyloidosis.Hans Lee, MD
Hans Lee, MD
Assistant Professor, Department of Lymphoma/Myeloma
Hans Lee, MD, is currently an Assistant Professor and Director of Multiple Myeloma Clinical Research in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center. Dr. Lee's research efforts are focused on advancing the care and treatment of patients with multiple myeloma, AL amyloidosis, and Waldenström macroglobulinemia. His research goals are directed towards novel approaches to treating multiple myeloma and AL amyloidosis through early phase investigator-initiated and industry-sponsored clinical trials with a strong translational emphasis to interrogate myeloma pathobiology and mechanisms of drug response and resistance. Furthermore, Dr. Lee has published his work in several peer-reviewed journals including the New England Journal of Medicine, Lancet Oncology, Blood, and Leukemia.Lisa Roth, MD
Lisa Roth, MD
Director, Pediatric Oncology
Lisa Roth, MD, is an Associate Professor of Pediatrics in the Division of Pediatric Hematology/Oncology at Weill Cornell Medical College. Also, she serves as the Director of the Pediatric Oncology Program and the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Roth serves as the Vice Chair for the Hodgkin Lymphoma Committee in the Children’s Oncology Group. Her laboratory research focuses on identifying novel therapeutic targets for pediatric lymphomas such as aggressive B-cell non-Hodgkin lymphoma. Dr. Roth’s laboratory work is closely tied to her clinical research where she is leading several national clinical trials focused on advancing therapy for children, adolescents, and young adults with Hodgkin and non-Hodgkin lymphoma.
Sharon Castellino, MD, MSc
Sharon Castellino, MD, MSc
Professor of Pediatrics
Sharon Castellino, MD, MSc, is the Professor of Pediatrics at Emory University School of Medicine and the Director of the Leukemia and Lymphoma Program at the Aflac Cancer and Blood Disorders Center in the Children’s Healthcare of Atlanta. In addition, she is a member of the Cancer Prevention and Control Research Program at Winship Cancer Institute. Dr. Castellino’s expertise is in the analysis of outcomes and late effects in patients with hematologic malignancies. Her research interests are in the areas of Hodgkin lymphoma and cancer survivorship. Furthermore, Dr. Castellino is the Scientific Chair for the Children’s Oncology Group (COG) Hodgkin Lymphoma committee and had been the study chair of several clinical trials for high-risk Hodgkin lymphoma.
Shirley D'Sa, MD, FRCP, FRCPath
Shirley D'Sa, MD, FRCP, FRCPath
Haematologist and Associate Professor
Shirley D'Sa, MD, FRCP, FRCPath, is a Haematologist and Associate Professor at University College London Hospital NHS Foundation Trust in London. She specialises in the management of patients with IgM-related conditions and paraproteinaemic neuropathies. Dr. D’Sa is the clinical lead for the UCLH Centre for Waldenström macroglobulinaemia (WM) and Related Disorders, and haematological lead in the Joint Neurohaematology Service. She is a principal investigator in several clinical trials in WM and cold agglutinin disease (CAD) and a committee member on the International Workshops on WM and British Society for Haematology Guidelines Group. Dr. D’Sa is a co-trustee with patients and colleagues in the UK Registered Charity, WMUK and the Chief Investigator for the Rory Morrison Registry project.
Carlos de Castro, MD
Carlos de Castro, MD
Professor of Medicine, Division of Hematologic Malignancies & Cell Therapy
Carlos de Castro, MD, is a Professor of Medicine at Duke University in the Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine and a member of the Duke Cancer Institute. His clinical research focuses on treatments for bone marrow failure conditions such as paroxysmal nocturnal hemoglobinuria (PNH), aplastic anemia, myelodysplastic syndromes, and acute leukemias. Dr. de Castro has served in several roles at Duke including Medical Director of the 9100 Malignant Hematology Ward, Medical Director of the Apheresis Unit, and Program Director of the Duke Hematology-Oncology Fellowship Program. He is on the NCCN panel for Myelodysplastic Disorders and serves as a member of the Medical Board of Directors for the Aplastic Anemia & MDS International Foundation.
Jorge Castillo, MD
Jorge Castillo, MD
Clinical Director
Jorge Castillo, MD, is an Associate Professor at Harvard Medical School and serves as the Clinical Director of the Bing Center for Waldenström Macroglobulinemia at the Dana-Farber Cancer Institute. He is the principal investigator in a series of clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. In addition, Dr. Castillo is a member of the NCCN Committee for Myeloma, Amyloidosis and Waldenström Macroglobulinemia. He has authored more than 275 peer-reviewed articles and has published his research in multiple journals. Dr. Castillo regularly attends international professional seminars, conferences, and patient support group meetings to lecture on the latest research and treatments for Waldenstrom's Macroglobulinemia.
Adam Olszewski, MD
Adam Olszewski, MD
Associate Professor of Medicine
Adam Olszewski, MD, is a hematologic oncologist specializing in the treatment of lymphomas. He is the Associate Professor of Medicine at The Warren Alpert Medical School of Brown University and conducts clinical research for patients with Hodgkin and non-Hodgkin lymphomas at the Lifespan Cancer Institute at Rhode Island Hospital, Providence, RI. Dr. Olszewski is a Research Scholar of the American Cancer Society and a current Research Scholar of the Leukemia & Lymphoma Society. He has multiple rewards from the American Society of Hematology and the National Institutes of Health. His current research is focused on developing immunotherapies and molecularly targeted approaches for the treatment of non-Hodgkin lymphoma, as well as genomic correlates of responsiveness to these therapies..jpg)
Zachariah DeFilipp, MD
Zachariah DeFilipp, MD
Director of BMT Clinical Research
Zachariah DeFilipp, MD, is an attending physician in the Hematopoietic Cell Transplant and Cell Therapy Program at the Massachusetts General Hospital Cancer Center. He serves as Director of BMT Clinical Research and an Assistant Professor in Medicine at Harvard Medical School. Dr. DeFilipp is involved in translational and clinical research initiatives to improve outcomes for patients undergoing allogeneic hematopoietic cell transplantation. His research is on the development of approaches to the prevention and treatment of graft-versus-host disease. Also, his research efforts have explored improving transplant outcomes for high-risk leukemia through the incorporation of targeted agents in pre- and post-transplant and examining late effects following amongst long-term transplant survivors.Yi-Bin Chen, MD, MS
Yi-Bin Chen, MD, MS
Director, Hematopoietic Cell Transplant & Cell Therapy Program
Yi-Bin Chen, MD, MS, is the current Director of the Hematopoietic Cell Transplant and Cell Therapy Program at Massachusetts General Hospital. In addition, Dr. Chen is the Rogers Endowed Chair and an Associate Professor of Medicine at Harvard Medical School. Moreover, he is a clinical researcher who has been on faculty for 15 years. His academic interests have spanned all areas of improving outcomes for patients undergoing hematopoietic cell transplant with recent major advances in novel therapies of GVHD and the incorporation of targeted maintenance therapies after transplant to prevent disease relapse. Dr. Chen lives in Needham, MA with his wife and two teenaged children. In his spare time, when not driving his children around, he enjoys boating and fishing in the waters off Cape Cod.
Lauren Pinter-Brown, MD, FACP
Lauren Pinter-Brown, MD, FACP
Health Sciences Professor of Medicine and Dermatology
Lauren Pinter-Brown, MD, FACP, is a UCI hematologist-oncologist who specializes in the diagnosis and treatment of patients with lymphomas. Dr. Pinter-Brown has interest in malignant lymphoma, with a particular focus on T-cell and skin lymphomas. Her clinical interests also include antiphospholipid, B-cell lymphoma, Hodgkin's lymphoma, mycosis fungoides, non-Hodgkins lymphoma, stem-cell transplant and Waldenstrom's disease. Dr. Pinter-Brown has made important contributions to several clinical trials that led to approval of new drugs for the treatment of T-cell lymphoma. Her research focus is on optimizing treatment options for patients with lymphoma, especially cutaneous and T-cell lymphomas. Her primary goal is to care for patients to ensure that they are able "to live their best life."
CME Information
Refining Management of Classical Hodgkin Lymphoma:This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD).
What’s on the Horizon for Pediatric Management and AYA SurvivorshipACKNOWLEDGEMENT
This activity is supported an educational grant from educational grant from Seagen Inc.DATE OF RELEASE/EXPIRATION
This activity was released on December 20, 2022 and is valid until December 20, 2023. Requests for credit must be made no later than December 20, 2023.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, hematologic oncologists, medical oncologists, hematopathologists, primary care providers, family practitioner internists, hematology/oncology nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists.STATEMENT OF NEED/PROGRAM OVERVIEW
New treatments are poised to expand the armamentarium for pediatric classical Hodgkin lymphoma (cHL). Given the high rate of long-term survival in the pediatric population, treatment selection should consider any anticipated late toxicities associated with therapy, as well as long-term follow-up and survivorship plans that effectively facilitate the transition from pediatric to young-adult care.
Join a panel of experts in hematology-oncology to discuss relevant treatment options for pediatric patients with cHL and individualization of treatment based on risk status and the latest guidelines. Panelists will review emerging treatment options in clinical trials and share strategies to monitor for treatment-related late effects and preserve quality of life during the transition from pediatric to adult care.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Apply guideline- and evidence-based approaches to the management of patients with pediatric cHL
- Discuss the rationale for new therapies and the clinical data supporting their utilization in the pediatric cHL population
- Evaluate strategies to formulate long-term follow-up plans considering the transition from being a pediatric patient to adolescence and young adulthood
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Sharon M. Castellino, MD, MSc
Professor of Pediatrics
Emory University School of Medicine
Director, Leukemia and Lymphoma Program
Children's Healthcare of Atlanta
Chair, Hodgkin Lymphoma Committee
Children’s Oncology Group
Consulting Fee: Seagen, Inc: Advisory board – no honorarium taken; MJH Life Sciences – CME speaker Lisa Giulino Roth, MD
Associate Professor of Pediatrics
Director, Pediatric Oncology
Director, Adolescent and Young Adult Lymphoma Program
Weill Cornell Medical College
Vice Chair, Hodgkin Lymphoma Committee, Children’s Oncology Group
Consulting Fee: Merck; Roche
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Rhys Williams, MSN, FNP-C, RN Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Lauren Sinclair Nothing to disclose Tariqa Ackbarali Nothing to disclose Vandana Gupta Nothing to disclose Alissa Yost Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
CD30‐Targeted Treatment Approaches for Patients with PTCL and CTCLThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD).ACKNOWLEDGEMENT
This activity is supported by an educational grant from Seagen, Inc.DATE OF RELEASE/EXPIRATION
This activity was released on August 17, 2022 and is valid until August 17, 2023. Requests for credit must be made no later than August 17, 2023.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.STATEMENT OF NEED/PROGRAM OVERVIEW
Treatment of T-cell lymphomas remains a challenge, as both peripheral and cutaneous T-cell lymphomas are rare malignancies. While CD30-targeted therapy has quickly become a welcome addition to the treatment armamentarium for T-cell lymphomas, the predictive value of CD30 expression continues to be debated.
Join Dr. Lauren Pinter-Brown for this session in the “Annual Rare Cancers and Blood Disorders Series” on tailoring diagnostic and management approaches for CD30-positive peripheral and cutaneous T-cell lymphomas. In this CME-accredited session, Dr. Pinter-Brown will discuss the prognostic and predictive value of CD30 expression, the impact of testing inconsistencies, the application of appropriate treatments, and important considerations for retreatment with CD30-targeted therapy.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Discuss the clinical application of testing for CD30 expression
- Evaluate practice strategies to improve integration of CD30‐targeted therapy and management of adverse events
- Apply evidence‐based and novel treatment approaches in the relapsed/refractory setting following CD30‐targeted therapy
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 0.5 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Lauren C. Pinter-Brown, MD
Professor of Medicine and Dermatology
University of California, Irvine
Consulting Fee: Kyowa-Kirin
Speakers’ Bureau: Acrotech Biopharma
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Rhys Williams, MSN, FNP-C, RN Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Tariqa Ackbarali Nothing to disclose Vandana Gupta Nothing to disclose Alissa Yost Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
Improving Quality of Life with Treatment Approaches in Graft versus Host DiseaseThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD).ACKNOWLEDGEMENT
This activity is supported by educational grants from Incyte Corporation and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, IncDATE OF RELEASE/EXPIRATION
This activity was released on June 9, 2022 and is valid until June 9, 2023. Requests for credit must be made no later than June 9, 2023.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.STATEMENT OF NEED/PROGRAM OVERVIEW
While it can be difficult to recognize complications associated with treatment of blood cancers, such as graft versus host disease (GvHD), timely and accurate diagnosis is imperative to improving patient outcomes. Delays in diagnosis frequently lead to additional complications, including a toll on the mental and emotional health of patients and caregivers.
Join two expert hematologists/oncologists as they shine a light on clinical nuances of acute and chronic GVHD, the impact of treatment delays, and advancements in disease understanding. Panelists will discuss existing and investigational targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors, identify treatment strategies after failure of systemic therapy for chronic GvHD and steroid-refractory disease for acute GvHD, and emerging long-term data including patient-reported outcomes.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Review the need for timely and accurate diagnoses of rare hematologic malignancies
- Identify patients with rare hematologic malignancies who would benefit from targeted therapies
- Evaluate data from practice-changing clinical trials on efficacy and safety of current and emerging targeted therapies for rare hematologic malignancies
- Implement effective strategies for management of individual patients with rare hematologic malignancies to improve clinical outcomes and patient quality of life
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Zachariah DeFilipp, MD
Director of BMT Clinical Research
Assistant Professor
Hematopoietic Cell Transplant and Cellular Therapy Program
Massachusetts General Hospital
Harvard Medical SchoolConsulting Fee: Syndax Pharmaceuticals, Inc., Kadmon Corp., Omeros Corp., Incyte, Corp., and MorphoSys AG.
Contracted Research: Incyte, Corp., Regimmune, Corp and Taiho Oncology, Inc.Yi-Bin Chen, MD, MS
Director, Hematopoietic Cell Transplant & Cell Therapy Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical SchoolConsulting Fee: Incyte, Daiichi, Abbvie, Gamida Cell, Novartis, Magenta
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Rhys Williams, MSN, FNP-C, RN Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Tariqa Ackbarali Nothing to disclose Sumera Ackbarali Nothing to disclose Alissa Yost Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
Systemic Therapy for Symptomatic Patients with Waldenström’s MacroglobulinemiaThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD).ACKNOWLEDGEMENT
This activity is supported an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.DATE OF RELEASE/EXPIRATION
This activity was released on June 1, 2022 and is valid until June 1, 2023. Requests for credit must be made no later than June 1, 2023.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.STATEMENT OF NEED/PROGRAM OVERVIEW
Rare hematologic malignancies like Waldenström’s macroglobulinemia are difficult to diagnose, have unclear symptoms that can overlap with other conditions, and significantly impact patient quality of life. A Bruton’s tyrosine kinase (BTK) inhibitor has been approved for Waldenström’s, while several investigational treatments are currently in clinical trials. As such, data continue to accumulate on current treatments and ongoing advances, making it difficult for oncologists and other healthcare professionals to stay up to date with the substantial information released on Waldenström’s and its management.
Join expert hematology/oncology faculty to discuss differential diagnoses of Waldenström’s macroglobulinemia, when to initiate specialist referrals, and rationales for the use of targeted therapies. Panelists will share the latest clinical data on the efficacy and safety of approved and emerging treatments and discuss how to best integrate these therapies into patient care to optimize outcomes and improve patient quality of life.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Review the need for timely and accurate diagnoses of rare hematologic malignancies
- Identify patients with rare hematologic malignancies who would benefit from targeted therapies
- Evaluate data from practice-changing clinical trials on efficacy and safety of current and emerging targeted therapies for rare hematologic malignancies
- Implement effective strategies for management of individual patients with rare hematologic malignancies to improve clinical outcomes and patient quality of life
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Adam Olszewski, MD
Associate Professor of Medicine
Alpert Medical School of Brown University
Rhode Island Hospital
Consulting Fee: Genmab, TG Therapeutics
Contracted Research: Adaptive Biotechnologies; Genentech/Roche; TG Therapeutics; Spectrum Pharmaceuticals; Celldex; Precision Biosciences; GenmabJorge J. Castillo, MD
Clinical Director
Bing Center for Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute
Consulting Fee: Abbvie, Beigene, Casma, Cellectar, Janssen, Roche, Polyneuron, Pharmacyclics
Contracted Research: Abbvie, AstraZeneca, Beigene, Pharmacyclics, TG Therapeutics
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Rhys Williams, MSN, FNP-C, RN Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Tariqa Ackbarali Nothing to disclose Sumera Ackbarali Nothing to disclose Alissa Yost Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
AL Amyloidosis: A Rare Blood Disorder with Multi-Organ ComplicationsThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD).ACKNOWLEDGEMENT
This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DATE OF RELEASE/EXPIRATION
This activity was released on April 20, 2022 and is valid until April 20, 2023. Requests for credit must be made no later than April 20, 2023.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.STATEMENT OF NEED/PROGRAM OVERVIEW
The wide range of symptoms for amyloidosis that overlap with other conditions often lead to diagnosis and treatment delays, and life-threatening organ damage. The recent approval of the first specific therapy for amyloidosis is changing the treatment landscape, creating a need for clinicians to stay abreast of new findings on the efficacy and safety of traditional and new treatments.
Join expert hematology/oncology faculty to review the variable clinical presentations of amyloidosis to ensure an earlier, accurate diagnosis. Expert panelists will also discuss the recent approval of daratumumab and hyaluronidase-fihj, a new treatment option for patients with amyloidosis. Clinicians will learn how to incorporate a higher index of suspicion and clinical data into patient care to optimize clinical outcomes and patient quality of life.EDUCATIONAL OBJECTIVES
-
After completing this activity, the participant should be better able to:
- Review the need for early and accurate diagnosis of amyloidosis to allow timely treatment and prevent life-threatening organ damage
- Identify patients with amyloidosis who would benefit from targeted therapy
- Evaluate data on efficacy and safety of current treatments and new treatment options for amyloidosis
- Implement effective strategies for management of individual patients with amyloidosis to improve clinical outcomes and patient’s quality of life
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Hans Lee, MD
Assistant Professor
Director, Multiple Myeloma Clinical Research
University of Texas MD Anderson Cancer Center
Consulting Fee: Bristol Myers Squibb, Celgene, Genentech, Karyopharm, Legend Biotech, GlaxoSmithKline, Sanofi, Pfizer, Monte Rosa Therapeutics, Immunitas Therapeutics, Oncopetides, Takeda Pharmaceuticals
Contracted Research: Amgen, Bristol Myers Squibb, Janssen, GlaxoSmithSkine, Regeneron, Takeda PharmaceuticalsVaishali Sanchorawala, MD
Professor of Medicine
Director, Amyloidosis Center
Boston Medical Center and Boston University School of Medicine
Consulting Fee: Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena
Contracted Research: Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum
Honoraria: Pfizer, Janssen
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Rhys Williams, RN, MSN, FNP Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Tariqua Ackbarali Nothing to disclose Sumera Ackbarali Nothing to disclose Alissa Yost Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
Cold Agglutinin Disease (CAD): Impact of a Rare Anemia and the Promise of New TherapiesThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD).ACKNOWLEDGEMENT
This activity is supported by an educational grant from Apellis Pharmaceuticals, Inc.DATE OF RELEASE/EXPIRATION
This activity was released on April 29, 2022 and is valid until April 29, 2023. Requests for credit must be made no later than April 29, 2023.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.STATEMENT OF NEED/PROGRAM OVERVIEW
Diagnosis of cold agglutinin disease (CAD) is usually slow, with misdiagnosed symptoms that are often incorrectly managed. Along with palliative treatments that have been the standard of care, the recent approval of the first therapy for CAD has added to the toolbox of strategies that clinicians use to manage this disorder.
As part of the 2022 “Annual Rare Cancers and Blood Disorders Series,” join an esteemed hematology/oncology expert to review the symptoms and pathology of CAD to aid in a timelier diagnosis. This activity will explore the need to coordinate care with a multidisciplinary team and the integration of a new treatment option into patient care to ensure better outcomes for patients. Participating clinicians will also learn about investigational therapies in development to benefit patients living with CAD.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Apply clinical coordination strategies to decrease the time to diagnosis for patients with CAD
- Anticipate physiological, psychological, and social impacts of CAD on patients
- Review emerging clinical trial data and the mechanisms of action of new therapies
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 0.5 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Shirley D’Sa, MD, FRCP, FRCPath
Consultant Haematologist & Associate Professor
UCLH Centre for Waldenström’s and Associated Conditions
University College London Hospitals NHS Foundation Trust
Consulting Fee: Janssen, Sanofi, BeiGene
Contracted Research: Janssen, Sanofi, BeiGene
Honoraria: Janssen, Sanofi, BeiGene
Speakers’ Bureau: Janssen, Sanofi, BeiGene
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Rhys Williams, RN, MSN, FNP Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Tariqua Ackbarali Nothing to disclose Sumera Ackbarali Nothing to disclose Alissa Yost Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
New Treatment Options for the Paroxysmal Nocturnal Hemoglobinuria (PNH) CommunityThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD).ACKNOWLEDGEMENT
This activity is supported by an educational grant from Apellis Pharmaceuticals, Inc.DATE OF RELEASE/EXPIRATION
This activity was released on April 29, 2022 and is valid until April 29, 2023. Requests for credit must be made no later than April 29, 2023.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.STATEMENT OF NEED/PROGRAM OVERVIEW
The symptoms of paroxysmal nocturnal hemoglobinuria (PNH) vary between patients which makes recognition of PNH difficult and creates significant diagnostic delays that take a toll on patients. The changing treatment landscape also challenges clinicians to stay up to date with new therapies while helping patients navigate a difficult disease course.
As part of the “Annual Rare Cancers and Blood Disorders Series,” join a renowned hematologist for this educational activity on the importance of an early diagnosis of PNH to ensure prompt and effective treatment. This session will review the clinical evidence on complement inhibitor therapies for PNH and explore strategies to integrate these treatments into patient care and manage treatment‐associated adverse events. Clinicians will also learn how to engage with patients to improve quality of life, find support, and share their experiences.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Discuss the heterogenous manifestations of PNH and the need for timely recognition of symptoms for early and accurate diagnosis of PNH
- Evaluate latest efficacy and safety data on current and emerging complement inhibitory therapies for children and adults with symptomatic PNH
- Integrate complement inhibitory therapies into the management of patients diagnosed with PNH
- Discuss how Global PNH registry can improve future determination of disease course and impact of treatment
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 0.5 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Carlos M. de Castro, MD
Professor of Medicine
Department of Medicine, Division of Hematologic Malignancies & Cell Therapy
Duke University
Consulting Fee: Alexion Pharmaceuticals, Apellis Pharmaceuticals, Biocryst Pharmaceuticals, Novartis Pharmaceuticals
Speakers’ Bureau: Apellis Pharmaceuticals
Data Safety Monitoring Committee: Regeneron Pharmaceuticals
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Rhys Williams, RN, MSN, FNP Nothing to disclose Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Tariqua Ackbarali Nothing to disclose Sumera Ackbarali Nothing to disclose Alissa Yost Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
.jpg)
